Navigation Links
Human Gene Therapy expands with robust new methods journal
Date:9/13/2011

New Rochelle, NY, September 13, 2011Mary Ann Liebert, Inc. announces the launch of a journal expansion, Human Gene Therapy Methods, to complement the flagship publication Human Gene Therapy. HGT Methods, which is officially Part B of Human Gene Therapy, is dedicated to publishing technological advances in cell and gene therapy that promote the development of gene therapy products into successful therapeutics. While Methods has always been a key element of the flagship journal, HGT Methods breaks new ground as the first publication to exclusively focus on the applications of gene therapy to product testing and development. HGT Methods will publish bimonthly and will premier in January 2012, with accepted articles appearing online ahead of print beginning in November 2011. Editor-in-Chief, James M. Wilson, MD, PhD, introduces this exciting journal expansion in this month's Editorial.

The field of gene therapy is rapidly evolving and holds great promise for its applications to treating human diseases, yet no product has been commercialized. Better methods are needed to evaluate the outcome of gene transfer technologies which are just entering the clinic. Likewise, standards for producing and characterizing products for distribution to patients have yet to be determined. HGT Methods answers the growing need for a central forum for nurturing, promoting, and advancing new technologies and methods that will ultimately pave the way for product development.

The existing leadership team of Human Gene Therapy, together with the newly appointed HGT Methods Editor, Thierry Vanden Driessche, PhD, will be responsible for the development and management of this new Journal.

"Gene therapy was predicted to revolutionize the practice of medicine," according to James M. Wilson, MD, PhD, Editor-in-Chief and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. "After 30 years of research and recent successes in Phase I clinical trials, it appears the revolution is upon us. For this revolution to realize its true potential we need to translate proof-of-concept studies in small human trials to commercialized products that become standard clinical practice. Human Gene Therapy Methods will be the venue for publishing the technological advances necessary for gene therapy products to be developed as successful therapeutics."


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
2. Scientists identify novel inhibitor of human microRNA
3. During exercise, the human brain shifts into high gear on alternative energy
4. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
5. Research shows Brazilian acai berry antioxidants absorbed by human body
6. Study: Bird diversity lessens human exposure to West Nile Virus
7. Human Microbiome Project awards funds for technology development, data analysis and ethical research
8. TheVisualMD.com launches new animated 3-D views of human body in action
9. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
10. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
11. Genetic based human diseases are an ancient evolutionary legacy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human Gene Therapy expands with robust new methods journal
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: